IL1B and cancer: Targeting the pro-inflammatory IL-1β pathway with canakinumab has been shown to inhibit the development and progression of lung cancer.167 The results from a phase II clinical trial showed that co-administration of anakinra with 5-fluorouracil and bevacizumab improves the median survival rate in patients with metastatic CRC.168 These promising results demonstrate that the anti-inflammasome strategy is an effective approach for cancer treatment and its efficacy can be improved with a combination therapy.